Bio-Path Holdings, Inc.

146 articles with Bio-Path Holdings, Inc.

• Bio-Path Holdings Reports First Quarter 2022 Financial Results

  5/17/2022

  Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments.

• Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

  5/10/2022

  Bio-Path Holdings, Inc. announced that it will host a live conference call and audio webcast on Tuesday, May 17, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022 and to provide a business overview.

• Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

  4/12/2022

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), today presented a poster highlighting preclinical BP1003 data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

• Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

  4/6/2022

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022.

• Bio-Path Holdings Reports Full Year 2021 Financial Results

  3/11/2022

  Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2021 and provided an update on recent corporate developments.

• Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

  3/8/2022

  Bio-Path Holdings, Inc. announced an upcoming poster presentation at the 2022 American Association for Cancer Research Annual Meeting, taking place in Atlanta, GA on April 8-13, 2022.

• Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

  3/4/2022

  Bio-Path Holdings, Inc. today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.

• Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

  1/5/2022

  Bio-Path Holdings, Inc. announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m.

• Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual MeetingPreliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients

  12/13/2021

  Bio-Path Holdings, Inc., (NASDAQ: BPTH), today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American Society of Hematology (ASH) Annual Meeting, taking place from December 11-14, 2021.

• Bio-Path Holdings Reports Third Quarter 2021 Financial ResultsConference Call to be Held Today at 8:30 A.M. ET

  11/12/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments.

• Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

  11/5/2021

  Bio-Path Holdings, Inc. announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview.

• Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

  11/4/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming poster presentation at the 2021 American Society of Hematology Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors

  10/27/2021

  Bio-Path Holdings, Inc., today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application to initiate a Phase 1/1b clinical trial of prexigebersen-A

• Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

  8/24/2021

  Bio-Path Holdings, Inc. announced that the U.S. Food and Drug Administration has reviewed and cleared the Investigational New Drug application for BP1002, the Company’s second drug candidate, for an initial Phase 1/ 1b clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.

• Bio-Path Holdings Reports Second Quarter 2021 Financial Results

  8/13/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments.

• Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

  8/6/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that it will host a live conference call and audio webcast on Friday, August 13, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021 and to provide a business overview.

• Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers

  6/22/2021

  Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that the United States Patent and Trademark Office has granted a new patent relating to the Company’s BP1003 program, a novel liposome-incorporated oligodeoxynucleotide inhibitor against Signal Transduction and Activator of Transcription-3.

• Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

  5/7/2021

  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 14, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.

• Bio-Path Announces Publication in Biomedicines

  4/22/2021

  Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen